These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 17056014)

  • 1. KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction.
    Okamoto K; Kitabayashi I; Taya Y
    Biochem Biophys Res Commun; 2006 Dec; 351(1):216-22. PubMed ID: 17056014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation.
    Wang C; Ivanov A; Chen L; Fredericks WJ; Seto E; Rauscher FJ; Chen J
    EMBO J; 2005 Sep; 24(18):3279-90. PubMed ID: 16107876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of Actinomycin D induced upregulation of Mdm2 in H1299 cells.
    Li L; Cui D; Zheng SJ; Lou H; Tang J
    DNA Repair (Amst); 2012 Feb; 11(2):112-9. PubMed ID: 22051195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest.
    Giono LE; Manfredi JJ
    Mol Cell Biol; 2007 Jun; 27(11):4166-78. PubMed ID: 17371838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rhythmic control of the ARF-MDM2 pathway by ATF4 underlies circadian accumulation of p53 in malignant cells.
    Horiguchi M; Koyanagi S; Hamdan AM; Kakimoto K; Matsunaga N; Yamashita C; Ohdo S
    Cancer Res; 2013 Apr; 73(8):2639-49. PubMed ID: 23580573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
    Wang H; Nan L; Yu D; Agrawal S; Zhang R
    Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDMX regulation of p53 response to ribosomal stress.
    Gilkes DM; Chen L; Chen J
    EMBO J; 2006 Nov; 25(23):5614-25. PubMed ID: 17110929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Yu D; Agrawal S; Zhang R
    Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
    Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
    Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.
    Duan W; Gao L; Wu X; Zhang Y; Otterson GA; Villalona-Calero MA
    Exp Cell Res; 2006 Oct; 312(17):3370-8. PubMed ID: 16934800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indole-3-carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells.
    Brew CT; Aronchik I; Hsu JC; Sheen JH; Dickson RB; Bjeldanes LF; Firestone GL
    Int J Cancer; 2006 Feb; 118(4):857-68. PubMed ID: 16152627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
    Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
    Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Any way you splice it: Mdm2 at the crossroads of tumor surveillance].
    Lents NH
    Ai Zheng; 2008 Sep; 27(9):993-7. PubMed ID: 18799043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actinomycin D synergistically enhances the cytotoxicity of CDDP on KB cells by activating P53 via decreasing P53-MDM2 complex.
    Wang L; Pang XC; Yu ZR; Yang SQ; Liu AL; Wang JH; Du GH
    J Asian Nat Prod Res; 2017 Jun; 19(6):630-643. PubMed ID: 28440085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents.
    Youlyouz-Marfak I; Gachard N; Le Clorennec C; Najjar I; Baran-Marszak F; Reminieras L; May E; Bornkamm GW; Fagard R; Feuillard J
    Cell Death Differ; 2008 Feb; 15(2):376-85. PubMed ID: 17992189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
    Lin K; Rockliffe N; Johnson GG; Sherrington PD; Pettitt AR
    Oncogene; 2008 Apr; 27(17):2445-55. PubMed ID: 17982489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression and clinical significance of P53 pathway-associated proteins in pancreatic carcinoma].
    Yu GZ; Zhu MH; Chen Y; Ni CR; Li FM
    Ai Zheng; 2005 Nov; 24(11):1398-403. PubMed ID: 16552971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
    Wunderlich M; Berberich SJ
    Oncogene; 2002 Jun; 21(28):4414-21. PubMed ID: 12080472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noise amplification in human tumor suppression following gamma irradiation.
    Liu B; Yan S; Gao X
    PLoS One; 2011; 6(8):e22487. PubMed ID: 21850227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Centromeric binding and activity of Protein Phosphatase 4.
    Lipinszki Z; Lefevre S; Savoian MS; Singleton MR; Glover DM; Przewloka MR
    Nat Commun; 2015 Jan; 6():5894. PubMed ID: 25562660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.